Neuropsychological Aspects of Sickle Cell Disease

Author(s):  
Jeffrey Schatz ◽  
Eve S. Puffer

The purpose of this chapter is to summarize current knowledge about the brain bases of the psychological effects of sickle cell disease (SCD). For the purpose of this chapter, we categorize two broad approaches commonly used to identify the behavioral correlates of brain function. Psychological or behavioral models are used that have been developed independent of the study of the nervous system. A common example of this approach is psychoeducational assessment, which focuses on constructs relevant to functional outcomes such as IQ scores and academic skills. Psychological models are also used for assessments that have been derived more directly from neuroscience. This approach typically involves assessing specific neurocognitive domains derived from theories of brain organization, such as language, visual-spatial, and executive functions. SCD offers a challenge to neuropsychologists because of the multiple factors to consider for understanding brain function. Because SCD is a genetic condition present from birth, the disease is likely to interact with developmental factors in infancy or early childhood. Because of social-historical factors, individuals with SCD are more likely than the general population to grow up in difficult social and economic conditions that place them at higher risk for some adverse brain effects. The disease itself also has specific effects on the brain that may lead to acquired brain injury during childhood or later in life. This context creates a challenge; there are multiple potential routes for brain effects that could have an impact on psychological functioning throughout the life span. We discuss research to date on a number of these factors, including pregnancy and birth risks, social and environmental factors in early childhood, and more direct effects of the disease on the brain. These factors are discussed in their likely order of impact based on current research, with direct effects of SCD on the brain having the most robust and well-established effects on neuropsychological functioning. An overview is presented in table 24-1. Mothers of children born with SCD either have SCD or trait. Data on pregnancy outcomes of mothers with SCD or trait indicate that most of these pregnancies are successful and without serious complications (Koshy, 1995; Sun, Wilburn, Raynor, & Jamieson, 2001).

1998 ◽  
Vol 8 (3) ◽  
pp. 535-543 ◽  
Author(s):  
R. Grant Steen ◽  
Wilburn E. Reddick ◽  
Raymond K. Mulhern ◽  
James W. Langston ◽  
Robert J. Ogg ◽  
...  

2019 ◽  
Vol 3 (23) ◽  
pp. 3982-4001 ◽  
Author(s):  
Ann T. Farrell ◽  
Julie Panepinto ◽  
C. Patrick Carroll ◽  
Deepika S. Darbari ◽  
Ankit A. Desai ◽  
...  

Abstract To address the global burden of sickle cell disease (SCD) and the need for novel therapies, the American Society of Hematology partnered with the US Food and Drug Administration to engage the work of 7 panels of clinicians, investigators, and patients to develop consensus recommendations for clinical trial end points. The panels conducted their work through literature reviews, assessment of available evidence, and expert judgment focusing on end points related to: patient-reported outcomes (PROs), pain (non-PROs), the brain, end-organ considerations, biomarkers, measurement of cure, and low-resource settings. This article presents the findings and recommendations of the PROs, pain, and brain panels, as well as relevant findings and recommendations from the biomarkers panel. The panels identify end points, where there were supporting data, to use in clinical trials of SCD. In addition, the panels discuss where further research is needed to support the development and validation of additional clinical trial end points.


2016 ◽  
Vol 63 (12) ◽  
pp. 2131-2138 ◽  
Author(s):  
Melanie E. Fields ◽  
Catherine Hoyt-Drazen ◽  
Regina Abel ◽  
Mark J. Rodeghier ◽  
Janet M. Yarboi ◽  
...  

1987 ◽  
Vol 77 (3) ◽  
pp. 156-160 ◽  
Author(s):  
M.A. Babiker ◽  
E.F. Ashong ◽  
H. Bahakim ◽  
A.M.A. Gader

2012 ◽  
Vol 34 (3) ◽  
pp. 196-201 ◽  
Author(s):  
Isaac Lima da Silva Filho ◽  
Georgina Severo Ribeiro ◽  
Patrícia Gomes Moura ◽  
Monica Longo Vechi ◽  
Andréa Cony Cavalcante ◽  
...  

Author(s):  
Bayat Elham

A wide sprectum of hematologic disorders affect the central and peripheral nervous system. These disorders include porphyria, thrombotic thrombocytopenic purpura-hemolytic uremic syndromes, sickle cell disease, plasma cell dyscrasias, monoclonal gammopathy, primary systemic amyloidosis, primary systemic amyloidosis, Waldonstrom’s macroglobulinemia, myeloproliferative syndromes, cryoglobulinemia, and polycythemia vera. Some, like porphyria, cause both central and peripheral nervous system manifestations including sensory/motor peripheral neuropathy, dysautonomia, pain, seizures, and abdominal pain. Others such as sickle cell disease primarily affect the brain and cause both clinically apparent strokes associated with a vasculopathy of large intracranial blood vessels, as well as less obvious microstrokes that cause progressive cognitive decline if not treated.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 512-512
Author(s):  
Charles T. Quinn ◽  
Pamela D. Hoof ◽  
Michael M. Dowling

Abstract Abstract 512 Background: Children with sickle cell disease (SCD) frequently suffer silent and overt cerebral infarction. Current screening and prevention techniques are suboptimal. Absolute cerebral oximetry is a rapid, non-invasive technique to measure hemoglobin (Hb) saturation in the brain. Cerebral tissue Hb saturation (SCTO2) is a physiologic measurement of the balance between oxygen supply and demand that could be used to identify regions of the brain at highest risk of infarction. We aimed to describe the distribution of SCTO2 in children with SCD and to identify its relationships with clinical, laboratory, and neuroimaging characteristics as well as response to transfusion. Methods: We used transcutaneous near-infrared spectrophotometry (CASMED FORE-SIGHT®) with bi-frontal probes to measure absolute SCTO2 in children with sickle cell anemia (SS), sickle-β0-thalassemia (Sβ0), sickle hemoglobin C disease (SC), and sickle-β+-thalassemia (Sβ+) during steady-state clinic visits or at the time of transfusion for stroke prophylaxis. Spearman correlation and multivariable modeling were used to test the relationships between SCTO2 and age, sex, genotype, Hb concentration, percent Hb F, percent reticulocytes, peripheral Hb saturation (SPO2), and cerebral arterial blood flow velocities by transcranial Doppler ultrasonography (TCD). Results: We studied 149 children (112 SS/Sβ0; 37 SC/Sβ+) with a mean age of 6.6±4.7 years (±S.D.). SCTO2 is known to be 65–80% in normoxic individuals with normal hemoglobin type and concentration breathing room air, but we found SCTO2 to be markedly lower in SCD: 53.2±14.2 (mean±SD) in SS/Sβ0 and 66.1±9.2% in SC/Sβ+ patients. SCTO2 was abnormally low (<65%) in 75% of SS/Sβ0 and 35% of SC/Sβ+ patients. SCTO2 correlated significantly with age (Spearman ρ=-0.54, P<0.001), sex (0.38, P<0.001), Hb concentration (0.38, P<0.001), percent reticulocytes (-0.3, P=0.002), percent Hb F (0.37, P<0.001), and SPO2 (0.4, P<0.001), but not TCD velocities as continuous measurements. However, when TCD velocities were categorized according to STOP criteria (abnormal and conditional vs. normal), SCTO2 was lower when the TCD velocity in the ipsilateral distal internal carotid artery was not normal (right-sided SCTO2: 39.2% for abnormal and conditional TCD vs. 57% for normal TCD, P=0.027). In multivariable models, the significant independent determinants of SCTO2 were SPO2 (P=0.004), Hb concentration (P=0.004), and age (P<0.001). Each unit decrease (1% absolute) in SPO2 gave an odds ratio of 1.4 or 1.5 for an abnormally low (<25th percentile) SCTO2 in the left and right hemispheres, respectively (AUC 0.84; P<0.001). Transfusion increased SCTO2 by 15.3% (absolute) on the left (P=0.002) and 23.6% (absolute) on the right (P=0.06). Two participants had severe unilateral cerebral vasculopathy demonstrated by magnetic resonance angiography. Both had a lower pre-transfusion SCTO2 on the side of the stenosis or occlusion (5-20% lower). The SCTO2 rose during the course of transfusion (10-30% absolute rise in SCTO2), and by the end of the transfusion the right- and left-sided SCTO2 measurements equalized. Conclusions: Cerebral tissue Hb desaturation is common in children with SCD and more severe in the SS/Sβ0 genotypes. Cerebral desaturation is associated with peripheral Hb desaturation, more severe anemia, increasing age, and occlusive vasculopathy, and it is ameliorated by transfusion. Cerebral desaturation, which can be detected rapidly and non-invasively, is a physiologic biomarker of brain at risk for ischemic injury. Cerebral oximetry should be studied further as a physiologic means to predict stroke and guide transfusion therapy for the prophylaxis of stroke in SCD. Disclosures: No relevant conflicts of interest to declare.


1981 ◽  
Vol 98 (1) ◽  
pp. 37-41 ◽  
Author(s):  
Michael C.G. Stevens ◽  
Richard J. Hayes ◽  
Shuba Vaidya ◽  
Graham R. Serjeant

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 2712-2712
Author(s):  
Adetola A. Kassim ◽  
Sumit Pruthi ◽  
Matthew Day ◽  
Michael R. DeBaun ◽  
Lori C. Jordan

Abstract Introduction: Neurologic complications are a major cause of morbidity in sickle cell disease (SCD). The cumulative cerebral risk for neurological complications in sickle cell anemia has been estimated around 50% by age 14 (Bernaudin et. al, 2011;Blood 4:1130-40). Silent cerebral infarcts (SCI), is the most commonly recognized cause of neurological injury, associated with cognitive difficulties (King et al, Am J Hematol 2014;89:162-7) found in 20-40% of children with SCD, more common in genotype SS or Sβ0 thalassemia. The prevalence of SCI has not been well studied in adults. The prevalence of intracranial saccular aneurysms by radiographic and autopsy series is estimated to be 3.2% in a population without comorbidity, a mean age of 50 years, and a 1:1 gender ratio. (Valk et al, Lancet Neurol 2011; 10: 626–36) while other investigators found a 1.8% prevalence and no increased incidence with age (Vernooij et al NEJM 2007;357:1821-8). The goal of this study was to assess the prevalence of neurologic morbidity, including SCI, overt stroke, and cerebral aneurysm, in a large cohort of adults with SCD. We hypothesized the SCI would be more prevalent in adults compared to children with SCD. Methods: Due to the high prevalence of cerebral infarcts in children with SCD, we elected to obtain as part of routine clinical practice, a MRI and magnetic resonance angiography (MRA) of the brain in adults with SCD in our Hematology clinic. As standard care if SCIs are seen, neurocognitive testing is recommended, and based on this testing and MRI results, appropriate patients are referred for vocational rehabilitation service. All MRIs and MRAs were reviewed by 2 board certified neuroradiologists and consensus findings were recorded including presence of cerebral infarcts, intracerebral hemorrhage, aneurysms and cerebralvasculopathy. All adults with SCD were followed by a single hematologist and were asked about neurological symptoms. Medical records were reviewed to see if stroke like symptoms had been reported. If no symptoms were reported and no abnormalities were documented on neurological examination, then infarcts were judged to be silent. Results: The study population included 94 adults with SCD (80% HbSS or Hb Sβ0 thalassemia; 11% HbSC, and 9% other), 51% males, median age 26 years, interquartile range (22-36 years) who had MRI of the brain and 88 had MRA of the brain. Of these, 91 MRIs were of sufficient quality to assess for the presence or absence of infarcts. Infarcts were present in 58% (53 individuals) with multiple infarcts in 40% (37 patients); infarcts were overt/symptomatic in 13% (12) and silent in 45% (41). Hemorrhages were present in 8 patients (9%) and of these, 7 of 8 also had infarcts present on MRI. MRI and MRA of the brain were felt of adequate quality to assess for vascular disease or aneurysm in 79 patients. Of these 7.5% (6 of 79 patients) had moyamoya vasculopathy and 7.5% (6 of 79 patients) had saccular aneurysms with no overlap between groups. All of the adults with moyamoya vasculopathy had overt strokes. The aneurysms were incidental findings and all were <5mm in size. Patients were referred to Neurosurgery for evaluation of aneurysmal lesions. Amongst the 12 adults with a history of overt stroke, 67% were on therapy (50% on hydroxyurea therapy; 17% on chronic blood transfusion therapy), 42% (5 of 12) received aspirin for stroke and 1 patient was already on warfarin for history of systemic thrombosis at the time of stroke. Conclusions: Silent cerebral infarctions are common in adults with SCD. Silent cerebral infarcts were present in 45% and over strokes had occurred in 13% of adults with SCD. Our aneurysm prevalence of 7.5% in a younger cohort (median age 26 years) suggests that adults with SCD may have a higher prevalence of cerebral aneurysms than the general population. Further study is warranted to assess whether SCD should be considered a comorbidity that confers a higher risk of cerebral aneurysm in adults. The optimal strategies for primary and secondary stroke prevention and to mitigate against the progressive cerebral vasculopathy in adults with SCD are still being debated. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document